State Key Laboratory of Oncology in South China & Department of Medical Oncology, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou 510060, China.
Eur J Cancer. 2012 Apr;48(6):882-8. doi: 10.1016/j.ejca.2011.09.004. Epub 2011 Oct 24.
The survival outcomes of patients with metastatic nasopharyngeal carcinoma (NPC) differ significantly between individuals. The aim of this study is to build a prognostic score model (PSM) incorporating circulating tumour markers for metastatic NPC in an epidemic area.
Seven hundred and ninety-nine patients with disseminated NPC were analysed retrospectively. Univariate and multivariable analyses were conducted using the Cox proportion hazards model. Factors analysed included patients' characteristics (gender, age group, performance status), circulating tumour-marker characteristics (Epstein-Barr virus (EBV) DNA level, EBV VCA-IgA level, lactate dehydrogenase (LDH) level, alkaline phosphatase (ALP) level), basic laboratory characteristics (leucocyte count, haemoglobin level, albumin level), and disease characteristics (presence of metastasis at presentation, disease-free interval, number of metastatic sites, specific metastatic sites). The PSM was built according to numerical score derived from the regression coefficients of each independent prognostic variable. The prognostic score of each patient was calculated by totalling up the scores of each independent variable.
Independent prognostic factors included performance status, age, haemoglobin level, LDH level, ALP level and EBV DNA level. Three prognostic groups based on PSM were obtained: low risk (total score=0-4); intermediate risk (5-8); high risk (9-12). Median survivals of the three groups were 25.5, 15.1 and 7 months, respectively, (P<0.001).
Clinical and laboratory characteristics can help guide the prognostication of patients with metastatic NPC in epidemic areas.
转移性鼻咽癌(NPC)患者的生存结局存在显著个体差异。本研究旨在建立一个包含流行地区转移性 NPC 循环肿瘤标志物的预后评分模型(PSM)。
回顾性分析 799 例转移性 NPC 患者。采用Cox 比例风险模型进行单因素和多因素分析。分析因素包括患者特征(性别、年龄组、体能状态)、循环肿瘤标志物特征(EBV DNA 水平、EBV VCA-IgA 水平、乳酸脱氢酶(LDH)水平、碱性磷酸酶(ALP)水平)、基本实验室特征(白细胞计数、血红蛋白水平、白蛋白水平)和疾病特征(初诊时转移、无疾病间期、转移部位数量、特定转移部位)。根据每个独立预后变量的回归系数,建立 PSM 数值评分。通过累加每个独立变量的得分,计算每位患者的预后评分。
独立预后因素包括体能状态、年龄、血红蛋白水平、LDH 水平、ALP 水平和 EBV DNA 水平。根据 PSM 分为低危(总分=0-4)、中危(5-8)、高危(9-12)三组。三组的中位生存时间分别为 25.5、15.1 和 7 个月(P<0.001)。
临床和实验室特征有助于指导流行地区转移性 NPC 患者的预后判断。